( d. Previously Dr.Carbone was Director...)Onconase has Potential as Chemopreventive Agent in Mesothelioma,,Reports World-Renowned Mesothelioma Researcher at AACR Annual,Meeting,Health

d. Previously, Dr. Carbone was Director of the Thoracic Oncology Program at Loyola University in Chicago, where he is also a tenured Professor at the Cancer Center, Department of Pathology. He also held scientific and academic positions at the National Institutes of Health (NIH), and at the University of Chicago.

Kuslima Shogen, Alfacell's chairman and chief executive officer, added: "Dr. Carbone is recognized as one of the world's leading researchers in mesothelioma. His remarks about ONCONASE at the AACR Annual Meeting reflect the interest of the international medical community in expanding the potential uses of ONCONASE."

About ONCONASE(R)

ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar ex
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Preclinical Data Show Alfacells Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
2. Researchers Identify Intracellular Pathway of Alfacells Onconase
3. In vivo Study Results Demonstrating Potential of Alfacells Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research
4. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
5. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. New Information on the Potential of Plasmin Shared at ISTH Congress
8. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
9. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
10. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
11. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme